BPHL Knockout HT29 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human colorectal adenocarcinoma cell line HT29. These cells harbor a targeted disruption of the BPHL (biphenyl hydrolase-like) gene, generating a loss-of-function model for studying prodrug activation and drug metabolism pathways. The polyclonal format reflects a heterogeneous editing outcome, avoiding the biases associated with single-cell clones and providing a robust platform for pharmacological and mechanistic investigations. This product enables researchers to dissect the role of BPHL in the bioactivation of ester-based prodrugs within an epithelial cancer context, facilitating studies on drug sensitivity, resistance, and metabolic regulation in colorectal cancer models.
HT29 is a well-characterized human colorectal adenocarcinoma cell line with epithelial morphology, originally isolated from a primary tumor of a 44-year-old female patient. This cell line is widely employed in oncology research due to its tumorigenic properties, ability to form xenograft tumors, and responsiveness to a range of chemotherapeutic agents. HT29 cells carry mutations in critical colorectal cancer-associated genes, including APC, TP53, and KRAS, rendering them a clinically relevant model for investigating drug response, resistance mechanisms, and tumor biology. Their robust growth characteristics and suitability for high-throughput screening make them an ideal host for targeted gene knockout studies, ensuring reproducible and consistent experimental outcomes.
BPHL encodes a serine hydrolase that catalyzes the hydrolysis of ester bonds in prodrugs, converting them into their active pharmacological forms. Notably, BPHL mediates the activation of the antiviral prodrug valacyclovir to acyclovir, the chemotherapeutic agent irinotecan to the topoisomerase I inhibitor SN-38, and valproate prodrugs to valproic acid. The enzyme operates within xenobiotic metabolism pathways and is transcriptionally regulated by nuclear factors NRF2, HNF4A, and PXR. Functionally, BPHL interacts with other carboxylesterases such as CES1 and CES2 within the ester hydrolase family, and its activity directly influences the intracellular accumulation of active metabolites including acyclovir, SN-38, and valproic acid. Thus, BPHL represents a critical molecular node connecting prodrug design to therapeutic efficacy in colorectal cancer and beyond.
In the HT29 cellular context, knockout of BPHL abolishes the enzymatic capability to hydrolyze key prodrugs, rendering the cells unresponsive to valacyclovir and significantly altering sensitivity to irinotecan. Specifically, disruption of BPHL blocks the irinotecan-to-SN-38 conversion pathway, abrogating the cytotoxic effects mediated by topoisomerase I inhibition. This polyclonal knockout model therefore serves as a powerful tool for differentiating BPHL-dependent drug activation from alternative metabolic routes. The heterogeneous knockout profile mirrors the natural clonal variability observed in tumor cell populations, providing a realistic platform for examining pharmacodynamic responses, resistance evolution, and metabolic plasticity in colorectal adenocarcinoma.
Typical research applications for BPHL Knockout HT29 Polyclonal Cells include prodrug activation studies through cell viability assays following treatment with valacyclovir or irinotecan, apoptosis signaling analysis via western blotting for markers such as cleaved caspase-3, and quantitative metabolite profiling by LC-MS or HPLC analysis of prodrug hydrolysis. Additional applications encompass clonogenic survival assays to assess chemoresistance and the generation of pharmacokinetic models of prodrug-metabolite conversion in colorectal cancer. These cells also enable investigation of compensatory esterase pathways mediated by CES1 and CES2. For further information, technical support, or inquiries regarding custom gene-editing projects, please contact Ascent Research.
